Raymond Fink
Endocrinology, Diabetes & Metabolism · la Mesa, CANPI 1164414652
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,715 and has fallen 98.0% since, to $34 in 2022.
Across 123 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$357
- Amgen$342
- AstraZeneca$315
- Lilly USA, LLC$255
- Merck$128
- Shire North American Group Inc$119
- plus $759 from 14 others
Across 890 payments — averaging $427.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$274K
- Eli Lilly$77K
- Dexcom, Inc.$22K
- Chiasma, Inc.$8K
- Amryt Pharma Holdings Ltd$204
What the payments were for
- Food & beverage$2,23398%
- Education$422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 19 | $357 |
| Amgen(2 entities) | 14 | $342 |
| AstraZeneca | 15 | $315 |
| Lilly USA, LLC | 19 | $255 |
| Merck | 8 | $128 |
| Shire North American Group Inc | 7 | $119 |
| Radius Health, Inc. | 5 | $117 |
| Dexcom, Inc. | 6 | $91 |
| AbbVie | 5 | $83 |
| Insulet Corporation | 4 | $76 |
| Novo Nordisk | 4 | $68 |
| Tandem Diabetes Care, Inc. | 3 | $56 |
| Companion Medical, Inc. | 2 | $54 |
| Boehringer Ingelheim | 3 | $50 |
| Valeritas, Inc. | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Mannkind Corporation | 2 | $25 |
| Johnson & Johnson | 1 | $24 |
| BD | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $15 |
How this compares
$2,275 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in la Mesa
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.